Analyst Price Target is $12.60
▲ +475.34% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Immuneering in the last 3 months. The average price target is $12.60, with a high forecast of $25.00 and a low forecast of $3.00. The average price target represents a 475.34% upside from the last price of $2.19.
Current Consensus is
Moderate Buy
The current consensus among 7 polled investment analysts is to moderate buy stock in Immuneering. This rating has held steady since March 2023, when it changed from a Hold consensus rating.
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Read More